Lead with the Fresenius Kabi–Phlow epinephrine onshoring pact — a US specialty-injectable supply deal that hits Juno's product focus, geography and signal-priority all at once. Behind it, two medical-device stories deserve a look (the Insulet Omnipod insulin-leak correction and Dexcom's stolen G7 lots), plus Kardigan's cardiovascular IPO filing. The Sun Pharma–Organon specialty acquisition is worth tracking as deal context even though it sits outside the four core markets. Most of the rest — oncology approvals, GLP-1 fibrosis data, ophthalmology drugs, AI biology models — is noise against our filter.
The model — what Ianstein scored against
Check the model first.
Every signal below was scored against this. If the model itself is wrong, or missing something Ian weighs, that is the most important thing to tell us — correct it here.
PRODUCT FOCUS — what counts as signal:
specialty injectables, generics, biosimilars, OTC, medical devices, cardiovascular.
Products, not disease-state or therapeutic detail.
REVENUE FLOOR: GBP 1-5M minimum. Below that, ignore.
GEOGRAPHIES: Canada, US, UK and Australia are the focus.
Elsewhere only when the item is a deal.
SIGNAL PRIORITY (highest first):
1. Active deals — licensing, M&A, supplier deals (the 48-hours-earlier edge)
2. Regulatory shifts
3. Competitive moves
4. Approvals
5. Litigation
6. Shortages and supply gaps
WHAT IS NOISE — score low or drop:
disease-state detail with no product angle; anything below the revenue floor;
markets outside the four unless the item is a deal; product areas outside the
focus list (for example ophthalmology, pure oncology) — surface low if it is a
deal, otherwise drop.
SCORING GUIDE:
Score each item 0-100 for fit against this model.
85-100 matches product focus + a core geography + a high-priority signal
60-84 matches two of those three dimensions
below 60 matches one dimension, or is off-focus even if it is a large story
The logic line must say plainly which criteria the item matched or missed.
Signals · ranked by Juno fit · check the logic on each
94fit
dealfiercepharma.com
Fresenius Kabi and Phlow ink US onshoring deal for epinephrine injection
Why: Direct competitive move in US specialty injectables with a domestic API anchor — reshapes a category Juno plays in.
Ianstein's logic · why it scored 94
Hits all three: specialty injectable + US + active supplier deal.
Held in — the vault, a local database: C:\Users\KevinFactor\Documents\Claude\Cpoint Capital\01-intelligence\ianstein-engine\data\ianstein.db Scored by — Claude Opus 4.7, against the model above De-duplicated — the same story from two feeds is collapsed before scoring